<p>Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States</p> - Concepedia

Concepedia

Publication | Open Access

<p>Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States</p>

DOI Full Paper Access

14

Citations

14

References

2019

Year

Maobai Liu, Sijie Han, Bin Zheng, Hongfu Cai, Jing Yang, Qian Zhuang, Na Li

Cancer Management and Research

Abstract

Pembrolizumab monotherapy as a second-line treatment for R/M HNSCC presents more health benefits in comparison with the standard, PD-L1 TPS and PD-L1 CPS groups in China and the US.

References

	Year	Citations

Page 1